Research trials have shown that injectable semaglutide can lead to about 15% body weight loss, on average.[1]

About Ozempic pens

Prescription Ozempic (semaglutide) in the UK

Ozempic is the one of the branded names of injectable semaglutide, which is licensed for the treatment of type 2 diabetes, and has been shown to help patients control blood sugar and lose weight (1).

In the UK, patients with type 2 diabetes can buy Ozempic if they have a prescription, or may be able to access it through the NHS if eligible. Ozempic is not licensed for weight loss, however a version of the medication which is licensed for weight loss (called Wegovy) is now available. Learn more about Wegovy here.

Holistic treatment

Who is Habitual?

Habitual provides two types of programmes:

Medication-based weight loss programmes which include a prescription, medication, and access to our behavioural resources including a mobile app and community support.

Type 2 diabetes remission programmes which combine total diet replacement with the same digital services included in medication plans.

Habitual does not prescribe Ozempic for weight loss, as it is only licensed for type 2 diabetes. Wegovy contains the same compound (semaglutide) and is licensed for weight loss.

What’s included

GLP-1 medication

Prescription semaglutide pen, delivered every 4 weeks to your door

Habitual app

Access to our custom-built app with daily behaviour change content and exercises to help you make lasting changes

Peer support

Optional peer support group on WhatsApp to connect with people on the same journey.

Personalised care

Chat to our dedicated Patient Care team. Ask questions, and get support when you need it.

FAQs

More information about Ozempic (semaglutide)

References

[1] “Once-weekly semaglutide in adults with overweight or obesity” (2021) New England Journal of Medicine, 385(1). Available at: https://doi.org/10.1056/nejmc2106918.
[2] Wilding, J.P. et al. (2022) “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The step 1 trial extension,” Diabetes, Obesity and Metabolism, 24(8), pp. 1553–1564. Available at: https://doi.org/10.1111/dom.14725.